Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma

Introduction to Neoadjuvant Chemotherapy

Neoadjuvant chemotherapy serves multiple critical roles in the management of invasive ductal carcinoma, including tumor downstaging to enable breast-conserving surgery, assessment of tumor chemosensitivity, and achievement of pathological complete response, which correlates with improved survival outcomes 1, 2, 3
The National Comprehensive Cancer Network guidelines establish that neoadjuvant chemotherapy increases breast conservation rates compared to upfront surgery, though it demonstrates no disease-specific survival advantage over postoperative adjuvant chemotherapy in stage II tumors 1, 2

For HER2-positive invasive ductal carcinoma, the incorporation of trastuzumab into neoadjuvant chemotherapy regimens is essential, increasing pathological complete response rates from 26% to 65.2% 2, 3
The recommended regimens from the adjuvant setting are appropriate for neoadjuvant use, including dose-dense AC followed by paclitaxel, or TCH (docetaxel, carboplatin, trastuzumab) for HER2-positive disease 4
Pathological complete response, defined as ypT0/isypN0 or ypT0ypN0, represents absence of residual invasive carcinoma in both breast and axillary lymph nodes and correlates with substantial improvements in survival 5, 6

Critical technical considerations include percutaneous clip placement under mammographic or ultrasound guidance before initiating chemotherapy to localize the prechemotherapy tumor volume, facilitating accurate postchemotherapy resection 1, 2, 3
Radiation therapy indications and treatment fields should be based on pretreatment tumor characteristics in patients receiving neoadjuvant chemotherapy 7
Following tumor response to preoperative chemotherapy, lumpectomy with appropriate axillary staging may be considered if breast-conserving therapy requirements are fulfilled 1, 2